607 - Radioligand therapy with Lutetium 177-labeled PSMA-I&T for metastatic castration-resistant prostate cancer: Clinical experience with 100 consecutive patients

Autor: Heck, M., Schwaiger, S., Knorr, K., Retz, M., Maurer, T., Janssen, F., D`Alessandria, C., Wester, H.-J., Gschwend, J., Schwaiger, M., Tauber, R., Eiber, M.
Zdroj: In European Urology Supplements March 2018 17(2):e874-e874
Databáze: ScienceDirect
Externí odkaz: